Fig. 2

KLF2-EVs improve heart function and ameliorate ventricular remodelling. A Mice received repeated low-dose injections of DOX (20 mg/kg in total) and then KLF2-EVs (100 µg of KLF-2 EVs dissolved in 200 µl of PBS) were administered two times via the tail vein. B Left ventricular function was assessed using echocardiography (representative short axis view of parasternal M-mode ultrasound). C Left ventricular ejection fraction (LVEF, %). D Left ventricular fractional shortening (LVFS, %). E Left ventricle end-diastolic diameter (LVIDd, mm). F Left ventricle end-systolic diameter (LVIDs, mm). G–J HE (G) and MT (I) staining were performed on heart sections prepared from mice 5 weeks after the first DOX injection. The ratio of HW/BW (H) and quantification of myocardial fibrosis in MT-stained sections (J) are shown. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns = not significant